Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Cervello, Melchiorre ^a   Bachvarov, Dimcho ^b,c   Lampiasi, Nadia ^a   Cusimano, Antonella ^a   Azzolina, Antonina ^a   McCubrey, James A ^d   Montalto, Giuseppe ^a,e  

^a CNR   (Italy)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d EAST CAROLINA UNIVERSITY   (United States)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DNA; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL DEATH; CELL METABOLISM; CELL STRAIN HEPG2; CELL STRAIN HUH7; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CARCINOGENESIS; MICROARRAY ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MICROARRAY ANALYSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84878921710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065569     Document Type: Article

References (50)

1. El-Serag HB, (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.
2. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, et al. (2002) Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 963: 13-20.
3. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, et al. (2012) Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3: 236-260.
4. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, et al. (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29: 688-696.
5. Cervello M, Montalto G, (2006) Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 12: 5113-5121.
6. Cervello M, Foderà D, Florena AM, Soresi M, Tripodo C, et al. (2005) Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol 11: 4638-4643.
7. Cusimano A, Foderà D, Lampiasi N, Azzolina A, Notarbartolo M, et al. (2009) Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. Ann N Y Acad Sci 1155: 300-308.
8. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, et al. (2009) Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci 1155: 293-299.
9. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, et al. (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36: 885-894.
10. Foderà D, D'Alessandro N, Cusimano A, Poma P, Notarbartolo M, et al. (2004) Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 1028: 440-449.
11. Lampiasi N, Foderà D, D'Alessandro N, Cusimano A, Azzolina A, et al. (2006) The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 17: 245-52.
12. Cusimano A, Foderà D, D'Alessandro N, Lampiasi N, Azzolina A, et al. (2007) Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Therapy 6: 1461-1468.
13. Lampiasi N, Azzolina A, Umezawa K, Montalto G, McCubrey JA, et al. (2012) The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett 322: 35-44.
14. Schmidt CM, Wang Y, Wiesenauer C, (2003) Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. J Gastrointest Surg 7: 1024-1033.
15. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J, (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858-3863.
16. Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, et al. (2001) Downregulation of wild-type beta-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Eur J Cancer 37: 512-519.
17. Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, et al. (2010) Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 9: 1399-1410.
18. Cao SS, Zhen YS, (1989) Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol. 24: 181-186.
19. Cervello M, Giannitrapani L, La Rosa M, Notarbartolo M, Labbozzetta M, et al. (2004) Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med. 13: 741-748.
20. Bachvarov D, Bachvarova M, Koumangaye R, Klein J, Pesquero JB, et al. (2006) Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. Biol Chem 387: 15-22.
21. Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, et al. (2011) COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS 15: 383-392.
22. Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, et al. (2011) Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol 5: 438-453.
23. Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, et al. (2012) Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 11: 2843-2855.
24. Inohara N, Ding L, Chen S, Núñez G, (1997) Harakiri: A novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 16: 1686-1694.
25. Gurzov EN, Ortis F, Cunha DA, Gosset G, Li M, et al. (2009) Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis. Cell Death Differ 16: 1539-1550.
26. Hao H, Chen C, Rao XM, Gomez-Gutierrez JG, Zhou HS, et al. (2012) E2F-1- and E2Ftr-mediated apoptosis: the role of DREAM and HRK. J Cell Mol Med 16: 605-615.
27. Pyrzynska B, Banach-Orlowska M, Teperek-Tkacz M, Miekus K, Drabik G, et al. (2013) Multifunctional protein APPL2 contributes to survival of human glioma cells. Mol Oncol 7: 67-84.
28. Nakamura M, Shimada K, Konishi N, (2009) The role of HRK gene in human cancer. Oncogene 27: S105-113.
29. Xu M, Chen X, Chen N, Nie L, Li X, et al. (2013) Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth. Am J Pathol 182; 84-95.
30. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H, (2005) TRB3 a novel ER stress-inducible gene, is induced via ATF-4CHOP pathway and is involved in cell death. EMBO J 24: 1243-1255.
31. Hall CA, Wang R, Miao J, Oliva E, Shen X, et al. (2010) Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 70: 8517-8525.
32. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, et al. (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101: 1279-1285.
33. Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, et al. (2011) YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 32: 389-398.
34. Zhang X, George J, Deb S, Degoutin JL, Takano EA, et al. (2011) The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30: 2810-2822.
35. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
36. Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761.
37. Basu S, Totty NF, Irwin MS, Sudol M, Downward J, (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11: 11-23.
38. Lapi E, Di Agostino S, Donzelli S, Gal H, Doman E, et al. (2008) PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 32: 803-814.
39. Levy D, Adamovich Y, Reuven N, Shaul Y, (2007) The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 14: 743-751.
40. Yee KS, O'Neill E, (2010) YAP1-friend and foe. Cell Cycle 9: 1447-1448.
41. Bertini E, Oka T, Sudol M, Strano S, Blandino G, (2009) YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 8: 49-57.
42. Yu B, Yang X, Xu Y, Yao G, Shu H, et al. (2009) Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 50: 948-957.
43. French DM, Lin BC, Wang M, Adams C, Shek T, et al. (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7: e36713.
44. Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, et al. (2012) Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS One 7: e52711.
45. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, et al. (2012) Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 12: 56.
46. Sawey ET, Chanrion M, Ca C, Wu G, Zhang J, et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19: 347-358.
47. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, et al. (2009) Fibroblast growth factor receptor 4 regulates proliferation, antiapoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50: 118-1127.
48. Cai C, Rajaram M, Zhou X, Liu Q, Marchica J, et al. (2012) Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. Cell Cycle 11: 1773-1781.
49. Lin BC, Wang M, Blackmore C, Desnoyers LR, (2007) Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282: 27277-27284.
50. Poh W, Wong W, Ong H, Aung MO, Lim SG, et al. (2012) Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer 11: 14.